| Document |
Document Title |
|
WO/2023/096387A1 |
The present invention relates to an organic light-emitting compound represented by [chemical formula A] or [chemical formula B], which can be used in an organic light-emitting device, and an organic light-emitting device comprising same,...
|
|
WO/2023/088229A1 |
Provided in the present invention is a method for synthesizing rivaroxaban. The method comprises: reacting an intermediate I and an intermediate II in an organic solvent in the presence of an alkali to obtain rivaroxaban, wherein the syn...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/091565A1 |
The current invention relates to nuclear receptor-binding SET domain-containing 2 (NSD2)- targeted protein degradation reagents and pharmaceutical compositions thereof and their utility as anti- cancer agents.
|
|
WO/2023/079128A1 |
The invention provides a process for manufacturing an aniline (2), wherein PG denotes hydrogen or an amino protective group, that is suitable for large-scale manufacturing of said aniline (2).
|
|
WO/2023/079569A1 |
The present disclosure provides a process for preparing a compound of Formula I, the process comprising: a. mixing a compound of Formula II with a compound of Formula III in a mole ratio range of 1:1 to 1.3:1 to obtain a first mixture; b...
|
|
WO/2023/078909A1 |
The present invention relates to compounds of formula (I), a delivery system based on photoresponsive cyclic acetal or ketal compounds capable of liberating in a controlled manner active volatile carbonyl compounds into the surrounding u...
|
|
WO/2023/078392A1 |
Provided are a 2-(aryl-2-yl) morpholine and a deuterated derivative thereof, a preparation method therefor and an application thereof. In particular, involved are the use of a compound shown by general formula (V) in the treatment of cen...
|
|
WO/2023/074527A1 |
The present invention addresses the problem of providing: a crystalline composition comprising a benzoxazine compound represented by general formula (1); and a method for producing same. As a solution, provided is a crystalline compositi...
|
|
WO/2023/066357A1 |
The present disclosure relates to fused cyclic compounds, preparation methods therefor, and medical uses thereof. Specifically, the present disclosure relates to the fused cyclic compound represented by general formula (I), a preparation...
|
|
WO/2023/064196A1 |
The present disclosure is directed to benzoxazinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or proph...
|
|
WO/2023/051716A1 |
Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate and eutectic or deuterated material thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inh...
|
|
WO/2023/055763A2 |
Treatment of CHD1L-driven cancers, including TCF transcription-driven cancers and EMT-driven cancers using CHD1L inhibitors. Small molecule inhibitors of CHDL1 which inhibit CHD1L ATPase and inhibit CHD1L-dependent TCF-transcription have...
|
|
WO/2023/044364A1 |
The present invention relates to protoporphyrinogen oxidase inhibitors of the general formula (I) where the variables are defined herein. The invention features processes and intermediates for preparing the benzoxazinones of formula (I),...
|
|
WO/2023/037818A1 |
The present invention addresses the problem of providing a means with which it is possible to inhibit a volatile component (sulfur-containing volatile component) which has an odor generated during production of a cured product by means o...
|
|
WO/2023/030434A1 |
An inhibitor of a prostate specific membrane antigen and a pharmaceutical use thereof. Specifically, the present solution belongs to the field of radiopharmaceuticals and relates to a compound represented by formula (IV) or a pharmaceuti...
|
|
WO/2023/034786A1 |
The disclosure provides processes for preparing Compound A, Compound E, Compound I, salts thereof, and/or stereoisomers thereof, as described herein.
|
|
WO/2023/026850A1 |
The present invention addresses the problem of providing: a novel benzoxazine compound which has excellent heat resistance, and is able to be cured under low-temperature conditions; a resin starting material composition which contains th...
|
|
WO/2023/021328A1 |
The current application relates to processes and intermediates thereof for the preparation of (S)-4-(3-(4-(tert-butoxycarbonyl)morpholin-2- yl)propanoyl)-3,5-difluorobenzoic acid (Compound 1A), a key synthetic intermediate in the synthes...
|
|
WO/2023/009204A1 |
Benzoxazine compounds represented by structures set forth herein; benzoxazine resins including same, hardenable resin compositions including benzoxazine resin described herein; hardenable resin compositions including at least one photoha...
|
|
WO/2023/281421A1 |
Hydrofluoroolefin amine compounds are represented by the following general formula (I): 5 (Rf 2-)(Rf 3CF2-)N-CH=CF-Rf 1 Formula I where Rf 1 is a linear, branched, or cyclic fluoroalkyl group containing 1-5 carbon atoms and may contain u...
|
|
WO/2023/274396A1 |
A class of benzazepine heterocyclic compounds that can be used as RORγt agonists and an application thereof in medicine, as well as a pharmaceutical composition comprising this class of compound and an application thereof in medicine. S...
|
|
WO/2023/278874A1 |
Provided herein are libraries of nerve-specific fluorescent contrast agents of substituted 8-methyl-phenoxazine compounds of Formula (I) with excitation and emission profile comparable to US FDA approved methylene blue (MB) and indocyani...
|
|
WO/2023/272720A1 |
PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor comp...
|
|
WO/2022/268218A1 |
Disclosed in the present invention are a preparation method for a heterocycloalkyl compound, and an intermediate and an application of the heterocycloalkyl compound. The present invention provides a preparation method for a compound repr...
|
|
WO/2022/268145A1 |
The present disclosure relates to an amide compound as represented by general formula I, or a prodrug, a pharmaceutically acceptable salt, a complex or a solvate thereof. The compound of the present disclosure has a new structure and has...
|
|
WO/2022/263820A1 |
The invention relates to compounds of formula (I): wherein R1 and X are as defined in the application, and their medical uses, for example for use in the treatment of α1-antitrypsin deficiency (A1AD or AATD).
|
|
WO/2022/262736A1 |
A class of benzoxazinone derivatives and a preparation method therefor, specifically related to a compound shown in formula (II), or a stereoisomer or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/240992A1 |
Described herein are TRPML1inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.
|
|
WO/2022/237849A1 |
The present invention relates to a NMDA receptor antagonist and use thereof. The NMDA receptor antagonist of the present invention is a compound of formula I below, or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a ...
|
|
WO/2022/218348A1 |
This invention provides a new synthesis method of lactam compounds, which is characterized in that, the method uses sodium chlorite as an oxidant, and under the catalysis of carbon dioxide, oxidizes cyclic amine compounds to lactam compo...
|
|
WO/2022/221629A1 |
Processes that use novel reagents for the removal of colored impurity during the preparation of Salcaprozic Acid and pharmaceutically acceptable salts thereof. The processes include hydrolysis of 8-(2,4-dioxo-1,3-benzoxazin-3-yl)octanoic...
|
|
WO/2022/217088A1 |
A dual-caged fluorogenic resorufin probe (CDA) has been developed that is stable under physiological condition with low background but becomes highly fluorescent upon β-lactamase/esterase activation and further oxidation. The probes of ...
|
|
WO/2022/214691A1 |
The invention relates to novel deuterated compounds of Formula (I) and their use as medicaments.
|
|
WO/2022/204046A1 |
Substituted naphthyl p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and the use of the substituted naphthyl p38α mitogen-activated protein kinase inhibitors and pharmaceutical compositions thereo...
|
|
WO/2022/198062A2 |
A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid ...
|
|
WO/2022/185877A1 |
The present invention provides a method for efficiently producing a hydrogenated compound under mild conditions. A catalyst composition which contains a Lewis acid and a metal nanoparticle catalyst that is obtained by loading a carrier...
|
|
WO/2022/174526A1 |
Provided are STAT3 small molecule inhibitors, which are naphtho[1,8-cd]isothiazol-5-one-1,1-dioxo derivatives or 1,4-dioxo-5-sulfamoyl-1,4-dihydronaphthalene derivatives. The derivatives are used for preparing medicaments for preventing ...
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/167866A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A), comprising formula (I). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, aut...
|
|
WO/2022/166990A1 |
Provided in the present invention are a 2-(substituted phenoxy)aromatic formic acid FTO inhibitor, a preparation method therefor and the use thereof, and specifically disclosed are a compound represented by formula (I), and the use of a ...
|
|
WO/2022/163555A1 |
The present invention addresses the problem of providing a production method having higher safety and efficiency in a method for producing a target benzoxazine compound that does not create a sudden temperature rise or smoke when introdu...
|
|
WO/2022/163551A1 |
The present invention addresses the problem of providing a method for producing a benzoxazine compound having a hydroxy group or a thiol group with high purity and high efficiency. As a solution, a method for producing a benzoxazine comp...
|
|
WO/2022/163553A1 |
The present invention addresses the problem of providing: a novel benzoxazine compound which can be cured under lower temperature conditions; a resin raw material composition which contains the benzoxazine compound; a curable resin compo...
|
|
WO/2022/163552A1 |
The present invention addresses the problem of providing: a novel benzoxazine compound that has excellent heat resistance, and can be cured under a low-temperature condition; a resin raw material composition containing the same; a curabl...
|
|
WO/2022/161462A1 |
A substituted morpholine derivative with a structure as shown in a formula (I). In addition, further disclosed are a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical composition and the use of the derivative.
|
|
WO/2022/158993A1 |
The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2): Formula (2), or a salt thereof, wherein R1 is hydroge...
|
|
WO/2022/156784A1 |
A preparation method for an imidazopyridine compound as shown in formula IV, and an intermediate thereof as shown in formula I or formula II. The imidazopyridine compound as shown in formula IV can antagonize a P2X3 receptor, and has the...
|
|
WO/2022/156783A1 |
The present invention provides a preparation method for an imidazopyridine compound as represented by formula IV and an intermediate as represented by formula I, formula II, or formula III. The imidazopyridine compound as represented by ...
|
|
WO/2022/153962A1 |
The problem to be solved by the present invention is to provide: a compound useful as a hole transport material for photoelectric conversion elements whereby electric current can be efficiently taken out; and a photoelectric conversion e...
|
